iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study

Globally, nearly half of patients with type 2 diabetes (T2D) do not successfully achieve target HbA1c with basal insulin, despite meeting fasting plasma glucose (FPG) targets. In this post hoc analysis of the LixiLan‐L study, we determined whether iGlarLixi, a fixed‐ratio combination of insulin glar...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Diabetes Obes Metab
Main Authors: Morea, Nicola, Retnakaran, Ravi, Vidal, Josep, Aroda, Vanita R., Liu, Minzhi, Saremi, Aramesh, Giorgino, Francesco
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2020
Teme:
Brief Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497103/
https://ncbi.nlm.nih.gov/pubmed/32363634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14077
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki